查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1422943

2024-2032 年按 MRSA 类型（医院获得性、社区获得性）、药物类别、疾病适应症、给药途径、配销通路和地区分類的 MRSA 药物市场

MRSA Drugs Market by MRSA Type (Hospital-Acquired, Community-Acquired ), Drug Class, Disease Indication, Route of Administration, Distribution Channel, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 149 Pages | 商品交期: 2-3个工作天内

价格

2023年，全球MRSA药物市场规模达到38亿美元。展望未来， IMARC Group预计到2032年市场规模将达到50亿美元，2024-2032年复合年增长率（CAGR）为3.11%。抗生素抗药性菌株的盛行率不断上升，由于住院时间延长而在医疗机构中持续接触多重抗药性微生物，以及临床试验数量不断增加，是推动市场发展的一些关键因素。

抗甲氧西林金黄色葡萄球菌 (MRSA) 是由抗抗生素金黄色葡萄球菌菌株引起的感染，通常发生在接受外科手术、接受静脉插管或皮肤接触的患者身上。 MRSA药物用作抗甲氧西林金黄色葡萄球菌感染的抗菌剂，以杀死或抑制它。它们抑制病原体的作用，同时增强患者的细胞合成和免疫力。最常见的 MRSA 药物包括甲氧芐啶-磺胺甲噁唑、克林霉素、米诺环素、利奈唑胺或多西环素。这些药物一般作为口服药物使用，疗程通常为七至十天。 MRSA 感染可能来自医院或社区，因此 MRSA 的治疗有时可能需要口服药物和静脉注射 (IV) 药物，具体取决于严重程度。有多种 MRSA 药物可用于治疗不同类型的感染，包括皮肤感染、骨骼感染、菌血症，甚至动物的人畜共通传染病。

MRSA 药品市场趋势：

大众中抗生素抗药性菌株的盛行率不断上升是推动市场成长的重要因素。这可以归因于全球范围内医院获得性感染（HAI）病例数量的增加。此外，由于住院时间延长，医疗机构中持续接触多重抗药性微生物，导致继发性院内感染的发生，进而推动了市场的发展。除此之外，越来越多的老年人口更容易感染抗甲氧西林金黄色葡萄球菌（MRSA），这也为市场提供了动力。此外，人们对不同形式的细菌感染的认识不断增强，导致耐甲氧西林金黄色葡萄球菌 (MRSA) 药物的使用量增加。与此一致的是，大量的产品创新、越来越多的临床试验以及新药物变体的引入正在市场上创造利润丰厚的成长机会。然而，开发新型 MRSA 药物变体所需的高成本是市场成长的主要限制因素。相反，各种诊断工具的技术不断发展，以及筛选抗生素抗药性菌株的临床试验计画数量不断增加，正在创造积极的市场前景。主要参与者进行的广泛研发（R＆D）活动进一步推动了市场。促进市场发展的其他一些因素包括针对现有产品的仿製药的出现、透过线上和线下有组织的平台轻鬆获得抗生素、快速城市化以及医疗支出的增加。

本报告回答的关键问题：

  • 迄今为止，全球 MRSA 药物市场表现如何？未来几年将如何表现？
  • 全球 MRSA 药物市场的驱动因素、限制因素和机会是什么？
  • 主要区域市场有哪些？
  • 哪些国家代表了最具吸引力的 MRSA 药物市场？
  • 基于 MRSA 类型的市场划分是怎样的？
  • 根据药物类别分類的市场是怎么样的？
  • 根据疾病迹象，市场的细分是什么？
  • 根据给药途径，市场的分化为何？
  • 基于配销通路的市场区隔是什么？
  • 全球MRSA药物市场的竞争结构如何？
  • 全球 MRSA 药物市场的主要参与者/公司有哪些？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 资料来源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球 MRSA 药品市场

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依 MRSA 类型

  • 医院获得性 (HA-MRSA)
    • 市场走向
    • 市场预测
  • 社区型 (CA-MRSA)
    • 市场走向
    • 市场预测

第 7 章：市场区隔：依药物类别

  • 脂肽
    • 市场走向
    • 市场预测
  • 噁唑烷酮类
    • 市场走向
    • 市场预测
  • 头孢菌素
    • 市场走向
    • 市场预测
  • 四环素
    • 市场走向
    • 市场预测
  • 叶酸拮抗剂
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 8 章：市场区隔：依疾病适应症

  • 皮肤感染
    • 市场走向
    • 市场预测
  • 骨骼和关节感染
    • 市场走向
    • 市场预测
  • 菌血症
    • 市场走向
    • 市场预测
  • 动物感染
    • 市场走向
    • 市场预测

第 9 章：市场区隔：依管理途径

  • 口服给药
    • 市场走向
    • 市场预测
  • 肠外给药
    • 市场走向
    • 市场预测

第 10 章：市场区隔：按配销通路

  • 医院药房
    • 市场走向
    • 市场预测
  • 零售药局
    • 市场走向
    • 市场预测
  • 网路药局
    • 市场走向
    • 市场预测

第 11 章：市场区隔：按地区

  • 北美洲
    • 美国
      • 市场走向
      • 市场预测
    • 加拿大
      • 市场走向
      • 市场预测
  • 亚太
    • 中国
      • 市场走向
      • 市场预测
    • 日本
      • 市场走向
      • 市场预测
    • 印度
      • 市场走向
      • 市场预测
    • 韩国
      • 市场走向
      • 市场预测
    • 澳洲
      • 市场走向
      • 市场预测
    • 印尼
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 欧洲
    • 德国
      • 市场走向
      • 市场预测
    • 法国
      • 市场走向
      • 市场预测
    • 英国
      • 市场走向
      • 市场预测
    • 义大利
      • 市场走向
      • 市场预测
    • 西班牙
      • 市场走向
      • 市场预测
    • 俄罗斯
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 拉丁美洲
    • 巴西
      • 市场走向
      • 市场预测
    • 墨西哥
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 中东和非洲
    • 市场走向
    • 市场细分：按国家/地区
    • 市场预测

第 12 章：驱动因素、限制与机会

  • 概述
  • 司机
  • 限制
  • 机会

第 13 章：价值链分析

第 14 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 15 章：价格分析

第16章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • AbbVie Inc.
    • Basilea Pharmaceutica Ltd
    • Crystal Genomics Inc.
    • Cumberland Pharmaceuticals Inc
    • Melinta Therapeutics Inc
    • Paratek Pharmaceuticals, Inc.
    • Pfizer Inc
Product Code: SR112024A6905

Abstract

The global MRSA drugs market size reached US$ 3.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 5.0 Billion by 2032, exhibiting a growth rate (CAGR) of 3.11% during 2024-2032. The rising prevalence of antibiotic resistant strains development, continual exposure to multidrug-resistant organisms in healthcare facilities due to prolonged hospital admission and the growing number of clinical trials represent some of the key factors driving the market.

Methicillin-resistant staphylococcus aureus (MRSA) is an infection caused by antibiotic-resistant strains of staphylococcus aureus that generally occurs in patients who undergo surgical procedures, receive intravenous tubing, or come in contact with each other skin-to-skin. The MRSA drugs are used as antimicrobial agents against methicillin-resistant staphylococcus aureus infection in order to kill or restrain it. They inhibit the actions of pathogens while enhancing the patient's cellular synthesis and immunity. The most common MRSA drugs consist of trimethoprim-sulfamethoxazole, clindamycin, minocycline, linezolid, or doxycycline. These drugs are generally used as oral medication, usually on a course of seven to ten days. MRSA infections can arise from hospitals or from community, hence the treatment for MRSA can sometimes involve the administration of oral medications and intravenous (IV) medications, depending on the severity. There are a wide variety of MRSA drugs available that can be used for the treatment of different types of infections, including skin infections, bone infections, bacteremia, and even zoonotic infections in animals.

MRSA Drugs Market Trends:

The rising prevalence of antibiotic resistant strains development among the masses is a significant factor driving the growth of the market. This can be attributed to the increase in the number of cases of hospital-acquired infections (HAIs) on the global level. Also, the continual exposure to multidrug-resistant organisms in healthcare facilities due to prolonged hospital admission is resulting in the development of secondary nosocomial infections, thereby propelling the market. In addition to this, the growing geriatric population that is more susceptible to developing MRSA infections is providing an impetus to the market. Moreover, the augmenting awareness regarding different forms of bacterial infection is leading to a higher uptake of MRSA drugs. In line with this, numerous product innovations, growing number of clinical trials and the introduction of novel drug variants are creating lucrative growth opportunities in the market. However, the high costs involved in developing novel MRSA drug variants is acting as major growth restraining-factor for the market. On the contrary, continual technological developments in various diagnostic tools, along with the increasing number of clinical trial programs for the screening of antibiotic resistant strains of bacteria, are creating a positive market outlook. The market is further impelled by extensive research and development (R&D) activities conducted by the key players. Some of the other factors contributing to the market include the emergence of generic drugs against presently available products, easy availability of antibiotics across online and offline organized platforms, rapid urbanization, and increasing medical expenditure.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global MRSA drugs market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on MRSA type, drug class, disease indication, route of administration, and distribution channel.

MRSA Type Insights

Hospital-Acquired (HA-MRSA)

Community-Acquired (CA-MRSA)

The report has provided a detailed breakup and analysis of the MRSA drugs market based on the MRSA type. This includes Hospital-Acquired (HA-MRSA) and Community-Acquired (CA-MRSA). According to the report, Hospital-Acquired (HA-MRSA) represented the largest segment.

Drug Class Insights

Lipopeptides

Oxazolidinones

Cephalosporin

Tetracycline

Folate Antagonist

Others

The report has provided a detailed breakup and analysis of the MRSA drugs market based on the drug class. This includes lipopeptides, oxazolidinones, cephalosporin, tetracycline, folate antagonist, and others. According to the report, lipopeptides represented the largest segment.

Disease Indication Insights

Skin Infections

Bone and Joint Infections

Bacteremia

Animal Infections

The report has provided a detailed breakup and analysis of the MRSA drugs market based on the disease indication. This includes skin infections, bone and joint infections, bacteremia, and animal infections. According to the report, skin Infections represented the largest segment.

Route of Administration Insights

Oral Administration

Parenteral Administration

The report has provided a detailed breakup and analysis of the MRSA drugs market based on the route of administration. This includes oral administration and parenteral administration. According to the report, parenteral administration represented the largest segment.

Distribution Channel Insights

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

A detailed breakup and analysis of the MRSA drugs market based on the distribution channel has also been provided in the report. This includes hospital pharmacies, retail pharmacies, and online pharmacies. According to the report, hospital pharmacies accounted for the largest market share.

Regional Insights:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for MRSA drugs. Some of the factors driving the North America MRSA drugs market include the rising medical expenditure, the increasing number of clinical trial programs, extensive research and development (R&D) activities conducted by key players, etc.

Competitive Landscape

The report has also provided a comprehensive analysis of the competitive landscape in the global MRSA drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include AbbVie Inc., Basilea Pharmaceutica Ltd, Crystal Genomics Inc., Cumberland Pharmaceuticals Inc., Melinta Therapeutics Inc, Paratek Pharmaceuticals, Inc., Pfizer Inc, etc.

Key Questions Answered in This Report:

  • How has the global MRSA drugs market performed so far and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global MRSA drugs market?
  • What are the key regional markets?
  • Which countries represent the most attractive MRSA drugs markets?
  • What is the breakup of the market based on the MRSA type?
  • What is the breakup of the market based on the drug class?
  • What is the breakup of the market based on the disease indication?
  • What is the breakup of the market based on the route of administration?
  • What is the breakup of the market based on the distribution channel?
  • What is the competitive structure of the global MRSA drugs market?
  • Who are the key players/companies in the global MRSA drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global MRSA Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by MRSA Type

  • 6.1 Hospital-Acquired (HA-MRSA)
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Community-Acquired (CA-MRSA)
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Drug Class

  • 7.1 Lipopeptides
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Oxazolidinones
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Cephalosporin
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Tetracycline
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Folate Antagonist
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by Disease Indication

  • 8.1 Skin Infections
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Bone and Joint Infections
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Bacteremia
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Animal Infections
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Route of Administration

  • 9.1 Oral Administration
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Parenteral Administration
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Market Breakup by Distribution Channel

  • 10.1 Hospital Pharmacies
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Retail Pharmacies
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Online Pharmacies
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia-Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 Drivers, Restraints, and Opportunities

  • 12.1 Overview
  • 12.2 Drivers
  • 12.3 Restraints
  • 12.4 Opportunities

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 AbbVie Inc.
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
      • 16.3.1.3 Financials
      • 16.3.1.4 SWOT Analysis
    • 16.3.2 Basilea Pharmaceutica Ltd
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
    • 16.3.3 Crystal Genomics Inc.
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
      • 16.3.3.3 Financials
    • 16.3.4 Cumberland Pharmaceuticals Inc
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
      • 16.3.4.3 Financials
    • 16.3.5 Melinta Therapeutics Inc
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
      • 16.3.5.3 Financials
    • 16.3.6 Paratek Pharmaceuticals, Inc.
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
      • 16.3.6.3 Financials
      • 16.3.6.4 SWOT Analysis
    • 16.3.7 Pfizer Inc
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
      • 16.3.7.3 Financials
      • 16.3.7.4 SWOT Analysis

List of Figures

  • Figure 1: Global: MRSA Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: MRSA Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: MRSA Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: MRSA Drugs Market: Breakup by MRSA Type (in %), 2023
  • Figure 5: Global: MRSA Drugs Market: Breakup by Drug Class (in %), 2023
  • Figure 6: Global: MRSA Drugs Market: Breakup by Disease Indication (in %), 2023
  • Figure 7: Global: MRSA Drugs Market: Breakup by Route of Administration (in %), 2023
  • Figure 8: Global: MRSA Drugs Market: Breakup by Distribution Channel (in %), 2023
  • Figure 9: Global: MRSA Drugs Market: Breakup by Region (in %), 2023
  • Figure 10: Global: MRSA Drugs (Hospital-Acquired (HA-MRSA)) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: MRSA Drugs (Hospital-Acquired (HA-MRSA)) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: MRSA Drugs (Community-Acquired (CA-MRSA)) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: MRSA Drugs (Community-Acquired (CA-MRSA)) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: MRSA Drugs (Lipopeptides) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: MRSA Drugs (Lipopeptides) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: MRSA Drugs (Oxazolidinones) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: MRSA Drugs (Oxazolidinones) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: MRSA Drugs (Cephalosporin) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: MRSA Drugs (Cephalosporin) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: MRSA Drugs (Tetracycline) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: MRSA Drugs (Tetracycline) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: MRSA Drugs (Folate Antagonist) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: MRSA Drugs (Folate Antagonist) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: MRSA Drugs (Other Drug Classes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: MRSA Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: MRSA Drugs (Skin Infections) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: MRSA Drugs (Skin Infections) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: MRSA Drugs (Bone and Joint Infections) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: MRSA Drugs (Bone and Joint Infections) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: MRSA Drugs (Bacteremia) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: MRSA Drugs (Bacteremia) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Global: MRSA Drugs (Animal Infections) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Global: MRSA Drugs (Animal Infections) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Global: MRSA Drugs (Oral Administration) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Global: MRSA Drugs (Oral Administration) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Global: MRSA Drugs (Parenteral Administration) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Global: MRSA Drugs (Parenteral Administration) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Global: MRSA Drugs (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Global: MRSA Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Global: MRSA Drugs (Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: Global: MRSA Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Global: MRSA Drugs (Online Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Global: MRSA Drugs (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: North America: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: North America: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: United States: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: United States: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Canada: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Canada: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Asia-Pacific: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Asia-Pacific: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: China: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: China: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Japan: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Japan: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: India: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: India: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: South Korea: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: South Korea: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Australia: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Australia: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Indonesia: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Indonesia: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Others: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Others: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Europe: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Europe: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Germany: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Germany: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: France: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: France: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: United Kingdom: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: United Kingdom: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Italy: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Italy: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Spain: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Spain: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Russia: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: Russia: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 80: Others: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 81: Others: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 82: Latin America: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 83: Latin America: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 84: Brazil: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 85: Brazil: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 86: Mexico: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 87: Mexico: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 88: Others: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 89: Others: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 90: Middle East and Africa: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 91: Middle East and Africa: MRSA Drugs Market: Breakup by Country (in %), 2023
  • Figure 92: Middle East and Africa: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 93: Global: MRSA Drugs Industry: Drivers, Restraints, and Opportunities
  • Figure 94: Global: MRSA Drugs Industry: Value Chain Analysis
  • Figure 95: Global: MRSA Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: MRSA Drugs Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: MRSA Drugs Market Forecast: Breakup by MRSA Type (in Million US$), 2024-2032
  • Table 3: Global: MRSA Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
  • Table 4: Global: MRSA Drugs Market Forecast: Breakup by Disease Indication (in Million US$), 2024-2032
  • Table 5: Global: MRSA Drugs Market Forecast: Breakup by Route of Administration (in Million US$), 2024-2032
  • Table 6: Global: MRSA Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 7: Global: MRSA Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 8: Global: MRSA Drugs Market: Competitive Structure
  • Table 9: Global: MRSA Drugs Market: Key Players